Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

incyte corp. - INCY

INCY

Close Chg Chg %
101.50 -1.04 -1.02%

Pre-Market

100.46

-1.04 (1.02%)

Volume: 2.09M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Trade Now

Company Overview: incyte corp. - INCY

INCY Key Data

Open

$101.20

 Day Range

99.69 - 102.47

52 Week Range

53.56 - 109.28

 Market Cap

$19.93B

Shares Outstanding

196.32M

 Public Float

194.20M

Beta

0.81

 Rev. Per Employee

N/A

P/E Ratio

17.02

 EPS

$6.11

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.07M

  

INCY Performance

1 Week
 
 -2.83%
 
1 Month
 
 -4.23%
 
3 Months
 
 17.15%
 
1 Year
 
 33.69%
 
5 Years
 
 22.08%
 

INCY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About incyte corp. - INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

INCY At a Glance

Incyte Corp.
1801 Augustine Cut-Off
Wilmington, Delaware 19803
Phone 1-302-498-6700 Revenue 4.24B
Industry Pharmaceuticals: Major Net Income 32.62M
Sector Health Technology 2024 Sales Growth 14.762%
Fiscal Year-end 12 / 2025 Employees 2,617
View SEC Filings

INCY Valuation

P/E Current 17.118
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 445.901
Price to Sales Ratio 3.429
Price to Book Ratio 3.875
Price to Cash Flow Ratio 43.36
Enterprise Value to EBITDA 73.46
Enterprise Value to Sales 2.934
Total Debt to Enterprise Value 0.005

INCY Efficiency

Revenue/Employee 1,620,640.81
Income Per Employee 12,462.744
Receivables Turnover 4.971
Total Asset Turnover 0.689

INCY Liquidity

Current Ratio 1.973
Quick Ratio 1.937
Cash Ratio 1.314

INCY Profitability

Gross Margin 91.094
Operating Margin 1.89
Pretax Margin 7.466
Net Margin 0.769
Return on Assets 0.53
Return on Equity 0.755
Return on Total Capital 0.93
Return on Invested Capital 0.747

INCY Capital Structure

Total Debt to Total Equity 1.75
Total Debt to Total Capital 1.72
Total Debt to Total Assets 1.101
Long-Term Debt to Equity 1.46
Long-Term Debt to Total Capital 1.435
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Incyte Corp. - INCY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.99B 3.39B 3.70B 4.24B
Sales Growth
+11.98% +13.67% +8.87% +14.76%
Cost of Goods Sold (COGS) incl D&A
187.34M 253.35M 315.15M 377.72M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
57.84M 67.86M 82.66M 89.25M
Depreciation
36.34M 46.35M 60.16M 65.65M
Amortization of Intangibles
21.50M 21.50M 22.50M 23.60M
COGS Growth
+15.90% +35.24% +24.39% +19.85%
Gross Income
2.80B 3.14B 3.38B 3.86B
Gross Income Growth
+11.73% +12.23% +7.62% +14.29%
Gross Profit Margin
+93.73% +92.54% +91.47% +91.09%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.16B 2.54B 2.73B 3.78B
Research & Development
1.46B 1.59B 1.63B 2.61B
Other SG&A
703.22M 955.78M 1.10B 1.18B
SGA Growth
-20.02% +17.60% +7.36% +38.65%
Other Operating Expense
- - - -
-
Unusual Expense
75.83M 107.71M (12.65M) 18.78M
EBIT after Unusual Expense
561.71M 491.85M 664.42M 61.37M
Non Operating Income/Expense
10.65M 39.93M 172.35M 257.54M
Non-Operating Interest Income
- - - 128.71M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.91M 2.67M 2.55M 2.28M
Interest Expense Growth
-12.24% +39.73% -4.31% -10.62%
Gross Interest Expense
1.91M 2.67M 2.55M 2.28M
Interest Capitalized
- - - -
-
Pretax Income
570.44M 529.12M 834.22M 316.63M
Pretax Income Growth
+345.65% -7.24% +57.66% -62.04%
Pretax Margin
+19.10% +15.59% +22.57% +7.47%
Income Tax
(378.14M) 188.46M 236.62M 284.01M
Income Tax - Current - Domestic
83.07M 128.22M 392.51M 366.64M
Income Tax - Current - Foreign
4.40M 3.14M 3.00M 2.93M
Income Tax - Deferred - Domestic
(465.53M) 58.40M (159.09M) (84.72M)
Income Tax - Deferred - Foreign
(75.00K) (1.31M) 195.00K (828.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
948.58M 340.66M 597.60M 32.62M
Minority Interest Expense
- - - -
-
Net Income
948.58M 340.66M 597.60M 32.62M
Net Income Growth
+420.79% -64.09% +75.42% -94.54%
Net Margin Growth
+31.76% +10.04% +16.17% +0.77%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
948.58M 340.66M 597.60M 32.62M
Preferred Dividends
- - - -
-
Net Income Available to Common
948.58M 340.66M 597.60M 32.62M
EPS (Basic)
4.3034 1.5345 2.6723 0.1575
EPS (Basic) Growth
+417.36% -64.34% +74.15% -94.11%
Basic Shares Outstanding
220.43M 222.00M 223.63M 207.11M
EPS (Diluted)
4.2715 1.5211 2.6451 0.1549
EPS (Diluted) Growth
+415.01% -64.39% +73.89% -94.14%
Diluted Shares Outstanding
222.07M 223.96M 225.93M 210.53M
EBITDA
695.38M 667.42M 734.43M 169.39M
EBITDA Growth
+468.93% -4.02% +10.04% -76.94%
EBITDA Margin
+23.29% +19.66% +19.87% +3.99%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 96.80
Number of Ratings 28 Current Quarters Estimate 1.948
FY Report Date 12 / 2025 Current Year's Estimate 6.735
Last Quarter’s Earnings 2.26 Median PE on CY Estimate N/A
Year Ago Earnings 1.076 Next Fiscal Year Estimate 7.87
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 20 7 23 22
Mean Estimate 1.95 1.71 6.73 7.87
High Estimates 2.45 2.12 7.16 9.33
Low Estimate 1.71 1.33 4.84 5.38
Coefficient of Variance 9.48 15.10 6.67 11.53

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 9
OVERWEIGHT 1 1 1
HOLD 14 14 15
UNDERWEIGHT 1 1 2
SELL 2 2 1
MEAN Overweight Overweight Overweight

Insider Actions for Incyte Corp. - INCY

Date Name Shares Transaction Value
Nov 26, 2025 Thomas Tray Principal Accounting Officer 23,573 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103 per share 2,428,019.00
Nov 26, 2025 Thomas Tray Principal Accounting Officer 24,173 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102 per share 2,465,646.00
Sep 19, 2025 Sheila A. Denton EVP & General Counsel 9,438 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 19, 2025 Sheila A. Denton EVP & General Counsel 33,200 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.15 per share 2,760,580.00
Sep 19, 2025 Sheila A. Denton EVP & General Counsel 33,478 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $64.25 per share 2,150,961.50
Jul 24, 2025 Steven H. Stein EVP & Chief Medical Officer 102,886 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $67.94 per share 6,990,074.84
Jul 18, 2025 Matteo Trotta EVP, GM, Dermatology US 15,016 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Sheila A. Denton EVP & General Counsel 33,985 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Lee Heeson EVP, Head of Incyte Intl 6,577 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Michael Morrissey EVP, Head of Tech. Operations 10,961 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Matteo Trotta EVP, GM, Dermatology US 13,154 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Vijay Iyengar EVP, GMAPPS 40,540 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.36 per share 2,771,314.40
Jul 18, 2025 Sheila A. Denton EVP & General Counsel 9,993 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2025 Sheila A. Denton EVP & General Counsel 20,461 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Matteo Trotta EVP, GM, Dermatology US 9,755 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.25 per share 665,778.75
Jul 18, 2025 Matteo Trotta EVP, GM, Dermatology US 11,841 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Mohamed Khairie Issa EVP, Head of US Oncology 19,735 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Barry P Flannelly EVP & General Manager US 35,149 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.36 per share 2,402,785.64
Jul 18, 2025 Sheila A. Denton EVP & General Counsel 18,419 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Mohamed Khairie Issa EVP, Head of US Oncology 85,252 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Incyte Corp. in the News